DigestRedComo funciona
Red
/
Empresas
Br
No verificado

BridgeBio Oncology Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
01/04/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
28/02/2025
Biotecnología
Farmacéutica
Salud
Oncología
Mercado laboral
Acciones y Obligaciones
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
09/01/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
23/12/2024
Eventos
Ferias y Congresos
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
09/12/2024
Industria
Biotecnología
Farmacéutica
Salud
Oncología
BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
18/11/2024
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Mercado laboral
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
30/10/2024
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0
09/09/2024
Mercado laboral
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer
Fuente
BridgeBio Oncology Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0